A Study of ERY974 in Patient With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT02748837

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02748837. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, An Anti-Glypican3 (GPC3)/CD3 Bispecific Antibody, in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican 3 positive advanced solid tumors until unacceptable toxicity or disease progression.

Study identification

NCT ID: NCT02748837
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Chugai Pharmaceutical; Industry
Enrollment: 29 participants

Conditions and interventions

Conditions

Solid Tumors

Interventions

ERY974 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 2016 (Type not available)
Primary completion: Aug 2019 (Actual)
Completion: Aug 2019 (Actual)
Last update posted: Aug 22, 2019

2016 – 2019

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
Not listed	Washington D.C.	District of Columbia	—	—
Not listed	Tampa	Florida	—	—
Not listed	Boston	Massachusetts	—	—
Not listed	Detroit	Michigan	—	—
Not listed	New York	New York	—	—
Not listed	Durham	North Carolina	—	—
Not listed	Providence	Rhode Island	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02748837, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 22, 2019 · Synced Nov 12, 2026